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Background: Matrix metalloproteinases (MMPs), together with their tissue inhibitors (TIMPs), remodel extracellular
matrix under physiological and pathological conditions and are implicated in pathogenesis of cardiovascular
diseases, cancer and in chronic inflammation. We have endeavoured to assess whether concentrations of MMPs,
TIMPs, and anti-inflammatory adiponectin are altered by pharmacological treatment of acute thyrotoxicosis or by
radioiodine therapy (RIT).
Material and methods: We measured serum concentrations of MMP-2, MMP-9, TIMP-1, TIMP-2, and adiponectin,
TSH, free T4 (FT4) and free T3 (FT3) in 15 patients (4 males), age (years) 51.8±15.3 (mean±SD) with hyperthyroidism
treated with thiamazole (Group 1) and in 20 subjects (2 males), treated for thyrotoxicosis with radioiodine, age
52.3±12.4 (Group 2), where blood samples were taken before RIT, visit 1 (V1), seven days post RIT, visit 2 (V2), and
two to three months post RIT, visit 3 (V3).
Results: In Group 1 there was no significant change in concentrations of MMP-2, MMP-9, TIMP-1, TIMP-2 or
adiponectin, despite a fall in FT4 and FT3 (8.74±4.79 pg/ml vs 3.54±2.40 pg/ml, for FT3, and 4.48 ±2.21 ng/ml vs
1.02±1.07 ng/ml, for FT4, p<0.001). In Group 2 RIT did not cause any acute change in serum MMP-2, MMP-9, TIMP-1
and TIMP-2 or adiponectin (V1 vs V2). However, there was a significant increase in serum adiponectin [from 15201
±8860 ng/ml (V1) to 19373±8657 ng/ml (at V3), p<0.05], and TIMP-2 at V3 [from 129±45 ng/ml (V1) to 149±38 ng/
ml (V3), p<0.01]. There was no significant change MMP-2, MMP-9 and TIMP-1 between V1 and V3. There was a
decrease in FT4 and FT3 from 24.4±15.4 pmol/l (V1) to 14.7±10.6 pmol/l (V3), and from 10.0±5.65 (V1) to 6.1±4.8
pmol/l (V2), p<0.01, for FT4 and FT3, respectively.
Conclusions: Radioiodine therapy of thyrotoxicosis does not alter serum MMP-2, MMP-9 or TIMP-1 concentrations
either acutely or after about three months of observation. An increase in serum adiponectin might reflect
favourable effects of radioiodine administration on cardiovascular risk factors, while an increase in TIMP-2 (principal
MMP-2 inhibitor) might lead to a decrease in free MMP-2 concentrations.
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The term matrix metalloproteinases (MMPs) refers to a
group of enzymes that remodel extracellular matrix in
various physiological and pathological conditions, such
as neoplasms, inflammatory and cardiovascular diseases
[1]. In particular, increased activity of MMPs in blood* Correspondence: alewin@csk.umed.lodz.pl
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reproduction in any medium, provided the orvessels has been implicated in formation of aneurysms
[2], as well as in formation of unstable atherosclerotic
plaques, in turn, leading to an increased risk of throm-
botic and embolic events, including myocardial infarc-
tions and strokes [3-5].
Adiponectin is an abundant plasma protein secreted
from adipocytes. It has been thought to be a key mol-
ecule in the development of type 2 diabetes mellitus and
metabolic syndrome, which are epidemiological targets
for preventing cardiovascular disease. In addition tol Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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anti-inflammatory, anti-atherosclerotic and vasoprotec-
tive actions. Furthermore, adiponectin affects signaling
in myocardial cells and exerts beneficial actions on the
heart after pressure overload and ischemia-reperfusion
injury [6,7].
There are reports [8,9], suggesting that even subclin-
ical thyrotoxicosis may be independently associated, with
an increased cardiovascular morbidity and mortality,
though there is no universal agreement on this subject
[10]. However, in contrast to thyroid neoplasms, concen-
trations of MMPs during treatment of thyrotoxicosis
have not been assessed, so far.
Pharmacological treatment of thyrotoxicosis carries a
definite risk of agranulocytosis that cannot be prevented
by routine complete blood count (CBC) monitoring of
asymptomatic patients [11]. Furthermore, pharmaco-
logical treatment generally does not lead to permanent
cure in subjects with toxic multinodular goitre, and is
associated with relapse in over 50% of cases of Graves’s
disease. For these reasons radioactive iodine treatment
(RIT) has been used for many years to treat thyrotoxi-
cosis. That treatment was considered to be safe enough,
to be prescribed even for children with Graves’ disease
[12]. There are, however, some data [13] suggestive that
RIT might lead to an increase in cardiovascular and
cancer mortality at least in some subjects, though a
definite causality remains to be proven [14]. Given po-
tential option of surgery (though also associated with
risks of complications), the safety of RIT is of para-
mount importance from the clinical view-point. For
these reasons, we have endeavoured to investigate
whether serum concentrations of MMPs, their inhibi-
tors (TIMP-1, TIMP-2) change during treatment with
radioiodine. For comparison we have also investigated
whether treatment of thyrotoxicosis per se might be
also associated with changes of serum concentrations
of MMPs, TIMPs and adiponectin.
Subjects and methods
The study involved two groups of subjects: Group 1 –
patients with thyrotoxicosis before and after treatment
with thiamazole, and Group 2 – patients with thyrotoxi-
cosis, who underwent therapy with radioactive iodine.
We studied 15 patients (4 males), age 51.8±15.3 years
(mean±SD), BMI 24.7±3.5 kg/m2, with hyperthyroidism
due to Graves’ disease (n=8), toxic adenoma (n=1) or
toxic multinodular goitre (n=6), treated with thiamazole.
Thyroid function, including concentrations of TSH, free
T4 (FT4) and free T3 (FT3), was assessed before treat-
ment and after 4–8 weeks. In all these subjects we also
measured concentration of matrix metalloproteinase 2
(MMP-2), matrix metalloproteinase-9 (MMP-9), tissue
inhibitor of matrix metalloproteinases-1 (TIMP-1),tissue inhibitor of matrix metalloproteinases-2 (TIMP-2)
and adiponectin, before and after treatment with
thiamazole.
Group 2 included 20 subjects (2 males), treated for
thyrotoxicosis with radioiodine, age 52.3±12.4 years,
BMI 27.4±4.66 kg/m2, where blood samples were taken
before RIT, visit 1 (V1), seven days post RIT, visit 2 (V2),
and two to three months post RIT, visit 3 (V3). The eti-
ology of thyrotoxicosis included Graves’ disease (n=10),
toxic adenoma (n=3) or multinodular goitre (n=7).
Radioactive iodine was administered according to the
protocol that involved thyroid goitre or nodule volume,
radioiodine uptake (T24) and radioiodine activity for 1
gram of thyroid tissue in the gland (depending on thy-
roid disease, see below). The formula for calculation the
dose of radioiodine was as follows:
dose of radioiodine (mCi) = [thyroid weight (g)1 x
radioiodine activity for 1 g of thyroid tissue (μCi/g)2] /
[(T24 (%)3 × 10],
where:
1. 1 ml of thyroid volume means 1 g of thyroid tissue,
2. radioiodine activity to be administered in adults: in
Graves’ disease - 80–150 μCi/1 g of thyroid tissue, in
toxic thyroid nodule - 150 μCi/1 g of thyroid tissue,
in toxic nodular goitre - 100–150 μCi/1 g of thyroid
tissue,
3. radioiodine uptake in % [15].
Measurements of MMP-2, MMP-9, TIMP-1, TIMP-2
and adiponectin were performed by R & D systems immu-
noassays (Human Quantikine ELISA kit, for MMPs and
TIMPs, Human Total Adiponectin /Acrp30 Quantikine
ELISA Kit - cataloque numbers: DMP2F0 for MMP–2,
DMP900 for MMP9, DTM100 for TIMP1, DTM200 for
TIMP-2 and DRP300 for adiponectin). Measurements of
FT4, FT3 and TSH were performed in Group 1 by the
means of Elecsys electrochemiluminescent immunoassay
(RocheW Diagnostics GmbH), while in Group 2 they were
performed by the means of Immulite 2000 XPi Immuno-
assay System (Siemens AG Germany).Statistical analysis
The data were analysed by means of simple descriptive
statistics of location and dispersion and Friedman
ANOVA for dependent samples (repeated measurements).
If the observed difference between all measurements was
significant, post hoc Tukey’s test was performed. In case of
non-normal distribution of data Mann-Whitney’s test for
a comparison of pairs of measurements. In all analyses,
statistical significance was considered achieved at a value
of p ≤ 0.05. All the calculations were derived by means of
Statistica v9.0 software.
Table 2 Descriptive statistics for the levels of TSH, FT4
and FT3 before radioiodine administration and at three
months after radioiodine administration (Friedman
ANOVA test), Group 2, n=20; SD – standard deviation;
SEM – standard error of mean; p – level of significance
Mean Med Min Max SD SEM p-value
TSH [mIU/l] 0.122 0.027 0.004 0.877 0.230 0.060 0.00012
1.74 0.82 0.03 7.89 2.27 0.59
FT4 [pmol/l] 24.4 18.8 13.3 72.5 15.4 4.0 0.014
14.7 13.9 3.9 58.3 10.8 2.4
FT3 [pmol/l] 10.0 7.7 4.1 24.0 5.6 1.4 0.016
6.1 5.1 2.2 25.8 4.8 1.1
Reference ranges: TSH - 0.4-4.0 mIU/l,
FT4 - 11.5-22.7 pmol/l (1 pmol/l x 0.0777 = ng/dl),
FT3 - 2.76-6.45 pmol/l (1 pmol/l x 0.6493 = pg/ml).
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Results
Results of the study are presented in Tables 1, 2, 3. 4,
Figure 1 and Figure 2. As expected, in patients from
Group 1, there was a marked fall in FT4 and FT3. There
was, however, no significant change in concentrations of
MMP-2, MMP-9, TIMP-1, TIMP-2 and adiponectin
(Table 1).
In patients from Group 2, there was also a significant
fall in FT4 and FT3, as well as an increase in TSH from
V1 to V3 (Table 2). There was no significant change in
MMP-2, MMP-9, TIMP-1 and adiponectin from V1 to
V2, but there was an increase in TIMP-2 concentrations
(p<0.05) (Table 3, Figure 1, Figure 2). Subsequently,
however, there was an increase in serum concentrations
of adiponectin, while concentrations of TIMP-2 still
remained elevated in comparison to V1 (p<0.01), see
Table 3, Figure 1 and Figure 2. Given that TIMP-2 is the
principal inhibitor of MMP-2, while TIMP-1 is the
principle inhibitor of MMP-9, we have endeavoured to
assess whether there is a possibility of a change in con-
centrations of free (i.e. active) MMP-2 and MMP-9. For
these reasons we have also assessed MMP-9/TIMP-1
and MMP-2/TIMP-2 ratio. Results of this analysis are
presented in Table 4. There was a decrease in MMP-2/
TIMP-2 ration (p<0.05), confirming the possibility of aTable 1 Descriptive statistics for the measurement results “be
mean median
MMP-2 – before [ng/ml] 671.7 668.0
MMP-2 – after [ng/ml] 616.7 612.0
MMP-9- before [ng/ml] 928.0 880.0
MMP-9 – after [ng/ml] 1238.7 1200.0
TIMP1- before [ng/ml] 374.7 390.0
TIMP1- after [ng/ml] 382.0 370.0
TIMP2- before [ng/ml] 207.7 205.0
TIMP2- after [ng/ml] 179.7 185.0
Adiponectin – before [ng/ml] 30807 31190
Adiponectin – after [ng/ml] 32755 34490
TSH - before [mIU/l]* 0.007 0.005
TSH – after [mIU/l] 1.064 0.03
FT3 – before [pg/ml]* 8.74 7.53
FT3 – after [pg/ml] 3.49 3.54
FT4 – before [ng/dl]* 4.48 2.21
FT4 – after [ng/dl] 1.02 1.07
p-value for the Mann-Whitney’s test for a comparison of pairs of measurement resu
*Reference ranges:
TSH - 0.27-4.2 mIU/l,
FT4 - 0.93-1.7 ng/dl (1 ng/dl = 1 pmol/l x 12.87),
FT3 - 2.6-4.4 pg/ml (1 pg/ml = 1 pmol/l x 1.54).fall in free MMP-2 concentrations at about 3 months
after radioiodine administration.
Discussion
To the best of our knowledge, this is the first study
where concentrations of matrix metalloproteinases and
their inhibitors were assessed before and after treatment
of thyrotoxicosis. The lack of significant change in con-
centrations of MMPs indicates that matrix metallopro-
teinases are unlikely to contribute to cardiovascular
morbidity and mortality associated with thyrotoxicosis.
To some extent, this thesis is also corroborated by lackfore” and “after” thiamazole therapy (Group 1; n=15)
SD min max p-value
73.4 551.8 824.0 0.78
76.2 446.0 733.0
464.8 300.0 1960.0 0.93
421.7 650.0 1890.0
109.8 70.0 500.0 0.83
70.8 280.0 510.0
42.8 150.0 280.0 0.18
38.2 105.0 245.0
12996 8450 52090 0.36
16638 2800 56100
0.003 0.005 0.01 0.013
1.74 0.0 5.77
4.79 4.02 16.5 0.0010
2.40 0.74 4.8
1.01 7.84 32.5 0.0010
0.44 0.34 1.7
lts “before” and “after”; SD – standard deviation; p – level of significance.
Table 3 Descriptive statistics for the levels of matrix metalloproteinases (MMP–2, MMP–9), their inhibitors (TIMP-1,
TIMP-2) and adiponectin at three time points, i.e. before radioiodine treatment (RIT), visit 1 (V1), seven days post RIT,
visit 2 (V2), and two-three months post RIT, visit 3 (V3), p-value for the Friedman ANOVA test, Group 2, n=20
Visits Mean Med Min Max SD SEM p-value
MMP-2 [ng/ml] V1 356 358.0 243.9 488.0 73.2 16.8 0.24
V2 349 348.8 221.8 470.3 63.3 14.9
V3 362 373.1 283.2 449.2 54.0 13.5
MMP-9 [ng/ml] V1 647 500.0 220.0 1390.0 343.8 78.9 0.56
V2 584 500.0 180.0 1790.0 378.5 89.2
V3 628 655.0 180.0 1020.0 261.9 65.5
TIMP-1 [ng/ml] V1 157 160.0 70.0 260.0 52.7 12.1 0.063
V2 173 170.0 100.0 260.0 40.8 9.6
V3 174 175.0 110.0 220.0 29.7 7.4
TIMP-2 [ng/ml] V1 129 120.0 75.0 285.0 45.3 10.4 0.012
V2 139 135.0 95.0 215.0 36.3 8.6
V3 149 137.5 90.0 220.0 38.3 9.6
Adiponectin [ng/ml] V1 15201 11890.0 3780.0 37970.0 8860.0 2032.6 0.0004
V2 13966 13020.0 3740.0 24990.0 6432.4 1516.1
V3 19373 17190.0 8010.0 38550.0 8657.4 2164.4
p-value for the Friedman ANOVA test, Group 2, n=20.
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tin before and after normalization of thyroid function.
Our results are in keeping with the study of Iglesias
et al. [16] who reported lack of any significant difference
in serum adiponectin in hyperthyroid (n=20) vs euthyr-
oid subjects (n=20). Also in the study of Chu et al. [17],
the authors reported that hyperthyroidism-associated in-
sulin resistance was not mediated by adiponectin levels.
It should be mentioned, however, that there are studies
suggestive of slightly higher adiponectin concentrations
in hyperthyroid subjects, particularly with Graves’ dis-
ease [18,19], though in these studies concentrations of
adiponectin have not been assessed in the same subjects,
before and after treatment.
In contrast to subjects treated with thiamazole, there
was a clear increase in adiponectin concentrations at
about three months after radioiodine administration. As,
to some extent this was also accompanied by a fall ofTable 4 Descriptive statistics for the levels of MMP-9/TIMP-1
radioiodine treatment (RIT), visit 1 (V1), seven days post RIT,
p-value for the Friedman ANNOVA test, Group 2, n=20
Visit Mean Med
MMP-9/TIMP-1 [ng/ml/ng/ml] V1 4.58 3.14
V2 3.53 2.95
V3 3.62 3.81
MMP-2/TIMP-2 [ng/ml/ng/ml] V1 2.88 2.85
V2 2.57 2.56
V3 2.52 2.45
p-value for the Friedman ANOVA test, Group 2, n=20.FT4 and FT3 to reference values, thus a question arose
whether some increase in adiponectin concentrations
might be observed after longer period of observation in
subjects treated with thiamazole. There is also a ques-
tion whether the observed increase in adiponectin in
subjects treated with radioiodine would be sustainable
over a longer period. This issue, needs to be addressed
by further research. Nevertheless, the observed increase
in vasoprotective adiponectin is reassuring, given some
recent controversies regarding cardiovascular safety of
treatment with radioactive iodine. As mentioned above
[6,7], adiponectin improves insulin sensitivity and exerts
anti-atherosclerotic effects in blood vessels. Indeed, there
are some studies [20] suggestive that the plasma leptin/
adiponectin ratio predicts first cardiovascular event, at
least in men. Furthermore, many cancer cell lines ex-
press adiponectin receptors, and adiponectin in vitro
limits cell proliferation and induces apoptosis. Recentand MMP-2/TIMP-2 ratio at three time points, i.e. before
visit 2 (V2), and two-three months post RIT, visit 3 (V3),
Min Max SD SEM p-value
1.90 14.71 3.36 0.77 0.22
0.90 8.95 2.18 0.51
1.06 6.2 1.49 0.37
1.59 3.73 0.54 0.13 0.03
1.80 3.20 0.39 0.09
1.91 3.6 0.53 0.13
Figure 1 Mean adiponectin concentrations and standard
deviations in subjects treated with radioactive iodine, i.e.,
before radioiodine therapy (RIT), visit 1 (V1), seven days post
RIT, visit 2 (V2), and two-three months post RIT, visit 3 (V3).
Statistical significance is marked by “*” (V1 vs V3, p<0.05).
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tumor growth-limiting properties of adiponectin [21].
There are also some studies that an association between
malignancy and low adiponectin concentrations exists,
for instance in the case of colorectal cancer [22]. We
also noticed that even though there was no significant
change in concentrations of matrix metalloproteinases
(MMP-2 and MMP-9), there was some increase in
TIMP-2 concentrations and a fall in MMP-2/TIMP-2
ratio that might reflect some decrease in concentrations
of free, i.e., presumably active MMP-2, as TIMP-2 is the
principal inhibitor of MMP-2, while TIMP-1 is the prin-
cipal inhibitor of MMP-9 [23]. Therefore, our data sup-
port a notion expressed previously that treatment withFigure 2 Mean MMP-2/TIMP2 ratio and standard deviations in
subjects treated with radioactive iodine, i.e., before radioiodine
therapy (RIT), visit 1 (V1), seven days post RIT, visit 2 (V2), and
two-three months post RIT, visit 3 (V3). Statistical significance is
marked by “*” (V1 vs V2, p<0.05), and by “**” (V1 vs V3, p<0.01).radioactive iodine appears safe [24], i.e., an observation
that was even applied to children treated with radio-
active iodine for Graves’ disease [25]. It should be men-
tioned, however, that cardiovascular safety of radioactive
iodine would also depend on meticulous follow-up of
patients who undergo this treatment as efforts must be
made to detect and to treat radioiodine-induced
hypothyroidism. If this is not done properly, then
hypothyroidism per se would increase a risk of subse-
quent cardiovascular disease [26-28]. It should also be
mentioned that stable concentrations of matrix metallo-
proteinases were also reassuring in terms of potential
risk of neoplastic disease. In this context, we noticed
that large study of Ron et al. [29], based on a data from
35 593 subjects, failed to reveal an increase in cancer
mortality in subjects treated with radioiodine.
In summary, our study demonstrates that radioiodine
treatment of thyrotoxicosis does not alter serum MMP-2,
MMP-9 or TIMP-1 concentrations, either acutely or after
about three months of observation. Though such data
alone are not enough to fully conclude upon the issue of
cardiovascular safety of radioiodine administration, the
lack of the above mentioned alterations of matrix metallo-
proteinases is at least reassuring. Furthermore, an increase
in serum adiponectin might reflect favourable effects of
radioiodine administration on cardiovascular and cancer
risk factors, while an increase in TIMP-2 (principal
MMP-2 inhibitor) might lead to a decrease in free
MMP-2 concentrations.
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